SM
TVTX icon

Sabby Management’s Travere Therapeutics TVTX Stock Holding History

Sabby Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,042
Closed -$147K – 201
2021
Q2 		$147K Buy
+10,042
New +$198K 0.02% 139
2016
Q2 		– Sell
-156,774
Closed -$2.54M – 329
2016
Q1 		$2.14M Buy
+156,774
New +$2.38M 0.11% 93

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Sabby Management's TVTX Position: Q3 2021 in Review

Sabby Management sold out of Travere Therapeutics (TVTX) in Q3 2021, closing a stake of 10,042 shares — an estimated $147K sold.

Sabby Management first reported a position in TVTX in Q1 2016 and held it in 2 quarters. The position peaked at $2.14M in Q1 2016. 148 funds tracked by Wall St. Rank hold TVTX as of Q3 2021.

  • Sabby Management reported no remaining Travere Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sabby Management sold 10,042 Travere Therapeutics shares in Q3 2021, an estimated $147K.
  • Sabby Management first reported a position in Travere Therapeutics in Q1 2016 and held it in 2 quarters.
  • Sabby Management's Travere Therapeutics position peaked at $2.14M in Q1 2016.
  • 148 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.